Journals / Turkish Journal of Pharmaceutical Sciences / 2009 / Cilt: 6 - Sayı: 1

Glipizid uzatılmis sahm gösteren tabletlerinin hazırlanması ve in vitro çözünme hızı

Preparation and in vitro dissolution of glipizide sustained release tablets

Pages
43–50
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, HPMC- based formulation comprising 10% glipizide, 50% HPMC, 39% lactose, and 1.0% magnesium stearate produced more linear release profile and comparable to reference product, Glipizide XL.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glipizide is an oral blood glucose lowering agent having short biological half life (2-4 hrs).
📊
Key Findings & Data:All the polymers were incorporated separately in the matrix system using wet granulation technique.
💡
Conclusion & Impact:However, HPMC- based formulation comprising 10% glipizide, 50% HPMC, 39% lactose, and 1.0% magnesium stearate produced more linear release profile and comparable to reference product, Glipizide XL.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Glipizid · Uzun etkili ilaçlar · Tabletler

Abstract

Glipizide is an oral blood glucose lowering agent having short biological half life (2-4 hrs). Since oral sustained release dosage form of this drug is less frequently available worldwide, therefore the present study was conducted to develop formulation of glipizide using ethyl cellulose (hydrophobic), high viscosity grades of hydroxypropyl methylcellulose (hydrophilic) and Kollicoat SR (hydrophobic- hydrophilic mixed). All the polymers were incorporated separately in the matrix system using wet granulation technique. In vitro dissolution studies were conducted in 450 ml 0.1M NaOH solution for 12 hrs testing intervals. Dissolution data indicated that as the amount of various polymers increased, the release rate of glipizide form matrix tablet was decreased. However, more sustaining effect was produced by HPMC based matrix tablets compared to EC or Kollicoat SR-based matrix tablets. However, HPMC- based formulation comprising 10% glipizide, 50% HPMC, 39% lactose, and 1.0% magnesium stearate produced more linear release profile and comparable to reference product, Glipizide XL.

Özet

Glipizid biyolojik yarılanma ömrü kısa (2-4 saat), oral kullanılanl bir kan glukozu düsürücü bir maddedir. Bu ilacın uzatılmis salm gösteren şeklinin dünyada daha az bulunması nedeniyle, bu çalisma etilselüloz (hidrofobik), yüksek viskoziteli hidroksipropil metilselüloz (hidrofilik) ve Kollicoat SR (hidrofobik-hidrofilik kar§imı) kullanlarak glipizid formülasyonu geli§tirmek üzere gerçekleştirildi. Tüm polimerler yaş granülasyon tekniği kullanlarak matriks system içine ayrı ayrı eklendi. In vitro çözünme hızı çalsmaları, 450 mL 0.1 M NaOH çözeltisinde 12 saat süreyle yürütüldü. Çözünme hızı bulgularna gore, farkl polimerlerin miktarlar arttikça glipizidin matriks tabletten salmı azaldı. Bununla birlikte, EC veya kollicoat SR matriks tabletler ile kar§ila§tirldiginda, HPMC esasl matriks tabletlerle daha fazla uzatılmis etki elde edildi. Diğer yandan, HPMC esasl ve %10 glipizid, %50 HPMC, %39 laktoz ve %1 magnesyum stearat içeren formülasyon, referans ürün Glipizide XL ’e gore daha doğrusal bir salm profili gösterdi.

🔖

Cite This Article

NAZIR, I., RAHMAN, N., MADNI, A. (2009). Glipizid uzatılmis sahm gösteren tabletlerinin hazırlanması ve in vitro çözünme hızı. Turkish Journal of Pharmaceutical Sciences, Cilt: 6 - Sayı: 1, 43–50. https://ajindex.com/articles/404048

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Budaveri, S., O’Neil, M.J., Heckelman, O.E., Kinneary, J. F. (Eds.). “The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals” 12th ed. Merck and Co., New Jersey, 1996
  2. Thomson, P.D.R., Montvale, N.J. “Physicians’ Desk Reference (PDR), electronic version, 2004
  3. Huang, Y.B., Wu, P.C., Chang, J.I., Tsai, M.J., Tsai. Y.H. ”Preparation and evaluation of sustained release microspheres of potassium chloride prepared with ethylcellulose” Int J. Pharm. 260,115-121, 2003
  4. Mario, G., Lucia, Z., Maria, E.S., Alessandra, M., Ferdinando, G., Andrea. G. “Modeling of drug release from partially coated matrices made up of a high viscosity HPMC” Int. J. Pharm. 276, 107–114, 2004
  5. Nicole, K., Owen. I.C. “Swelling and erosion properties of (Hypromellose) matrices:influence of agitation rate and dissolution medium composition” Int. J. Pharm. 279,141–152, 2004
  6. Zafer, I., Almas, B., Muhammad, A. “Controlled-release naproxen using micronized ethyl cellulose by wet-granulation and solid-dispersion method” Drug Dev Ind Pharm, 28, 129-134, 2002
  7. Parojcic, J., Duric, Z., Jovanovic, M., Ibric, S. “An investigation into the factors influencing drug release from hydrophilic matrix tablets based on novel carbomer polymers” Drug Deliv, 11, 59-65, 2004
  8. Focher, B., Marzetti, A., Sarto, V., Baltrame, P.L., Carmitti, F. “Cellulosic materials: Structure and enzymatic hydrolysis relationships” J Appl. Polym. Sci. 29, 3329-3338, 1984
  9. Droin, A., Chaumat, C., Rollet, M., Taverdet, J.L., Vernaud, J.M.“Model of matter transfers between sodium salicylate Eudragit matrix and gastric liquid” Int. J. Pharm. 27, 33-243,1985
  10. Armand, J.Y., Magnard, F., Bouzon, J., Rollet, M., Taverdet, J.L., Vernaud, J.M. “Modelling of the release of drug in gastric liquid from spheric galenics form with eudragit matrix” Int. J. Pharm, 40, 33-41, 1987
  11. Bidah, D., Vernaud, J.M. “Kinetics of in vitro release of sodium salicylate-eudragit matrix and gastric liquid” Int. J. Pharm, 27, 233-243, 1990
  12. Desai, S.J., Simonelli, A.P., Higuchi, W.I. “Investigation of factors influencing release rate of solid drug dispersed in inert matrices” Int. J. Pharm., 54, 1459-1464, 1965
  13. Farhadieh, B., Borodkinand, S., Budden-Hugen, J.D. “Drug release from methyl acrylate-methyl methacrylate copolymer matrix: Kinetics of Release” J. Pharm. Sci, 60, 209-212, 1971
  14. Wildschek, BASF; Germany. “Sustained release formulations based on polyvinyl acetate” Pharmatech, 2006
  15. Alderman